Why Is GeneDx Stock Up Today?
Record test volume and a revenue beat, but reimbursement per test held flat — and management is naming that as the real constraint on earnings.
- GeneDx missed Q2 2026 adjusted EPS — $(0.28) versus a $(0.19) estimate — though revenue of $114.440 million beat the $111.011 million estimate, as exome and genome test volume hit a quarterly record above 30,000 tests. Shares rose 9.286%.
- The blended average reimbursement rate held at $3258 per test, roughly flat and in line with expectations — volume is growing faster than the per-test economics, which is the real tension behind the EPS miss.
- Management explicitly framed reimbursement, not demand, as the company's biggest opportunity: CEO Katherine Stueland said the company is "under-earning on our potential" and expects payer coverage expansion and internal revenue-cycle improvements to lift collections starting in the back half of the year.
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % | Vol vs normal |
|---|---|---|---|---|---|---|---|
| WGS | — | — | — | — | +1.77% | +9.29% | — |
GeneDx missed Q2 2026 adjusted EPS — $(0.28) against a $(0.19) estimate — though revenue of $114.440 million beat the $111.011 million estimate. Exome and genome testing volume reached a quarterly record above 30,000 tests. Shares rose 9.286% on the day.
Volume is outrunning per-test economics, and that's the real story
The blended average reimbursement rate held at $3258 per test, roughly flat sequentially and in line with company expectations. When test volume hits a record and revenue beats estimates, but the per-test reimbursement rate doesn't move and EPS still misses, the gap is explained by volume growing faster than the economics of each individual test — more genetic tests are being run and billed, but the amount collected per test isn't yet capturing the full value of that growth.
Management is naming reimbursement as the constraint, not demand
CEO Katherine Stueland said demand for GeneDx's rare-disease genetic testing services "has never been higher," while explicitly framing reimbursement improvement as the company's largest opportunity, stating GeneDx is "under-earning on our potential." That is a specific, named constraint: the company's own leadership is pointing at payer coverage and internal revenue-cycle processes — not demand for the tests themselves — as the gap between current results and what the underlying test volume should be worth. Full-year 2026 revenue guidance of $475-490 million was reaffirmed, with management expecting a meaningful collection-rate uplift starting in the fourth quarter.
What to watch
The blended average reimbursement rate per test in Q4 2026 is the specific number that tests whether management's expected collection-rate uplift actually arrives on the timeline it named.
Sources
-
GeneDx Holdings Corp. - Form 8-K, Q2 2026 Results Press Release
— SEC EDGAR
Q2 2026 adjusted EPS and revenue versus estimates.
-
GeneDx Holdings Corp. (WGS) Slid as Revenue Fell Short of Expectations
— Insider Monkey
Record quarterly test volume and the blended average reimbursement rate per test.
-
GeneDx reaffirms 2026 revenue guidance of $475M-$490M while expecting meaningful collection-rate uplift starting in Q4
— Seeking Alpha
Reaffirmed FY2026 revenue guidance range and management's reimbursement-improvement commentary.
Never miss the next market-moving story
Seven market specialists, with experience dating back to 2006, watch global markets and U.S. stocks of every size. Start Pro to get the full live feed, clear context, measured price moves, search, watchlists, and alerts.
Start Pro — $29 for 7 days Watch WGS live -- free